Skip to main content
SpringerLink
Log in

ICER's final report recommends pricey drug for retinal disease

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Final Report: Broader Benefits of Voretigene Neparvovec to Affected Individuals and Society Provide Reasonable Long-Term Value Despite High Price. Internet Document : 14 Feb 2018. Available from: URL: https://icer-review.org/announcements/voretigene-final-report/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER's final report recommends pricey drug for retinal disease. PharmacoEcon Outcomes News 797, 3 (2018). https://doi.org/10.1007/s40274-018-4712-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4712-x

Search

Navigation